


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

**VOLUNTARY ANNOUNCEMENT
ENTER INTO STRATEGIC BIOSIMILARS PARTNERSHIP WITH STADA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Company, and STADA Arzneimittel AG (“**STADA**”) have entered into a strategic biosimilars partnership (the “**Partnership**”) to expand patient access to biosimilar medicines across multiple territories.

Terms

Subject to the terms and conditions of the Agreement, CTTQ will receive an upfront payment and will be eligible for potential development, regulatory and sales milestone payments of up to €53 million, as well as double-digit profit share for the pembrolizumab biosimilar candidate in the Licensed Territory.

CTTQ shall grant STADA an exclusive license to commercialize the pembrolizumab biosimilar (development code: TQB3570, anti-PD-1 monoclonal antibody) in the European Union, Switzerland, the United Kingdom and the Commonwealth of Independent States (the “**Licensed Territory**”). The Partnership also includes options to add up to three additional biosimilar molecules across oncology and immunology indications.

CTTQ will lead the development, manufacturing and commercial supply of the biosimilar candidates in the Licensed Territory. STADA will hold the marketing authorizations and have exclusive sales and marketing rights in the Licensed Territory, and will also have options for the United States of America and the member states of the Gulf Cooperation Council (GCC).

Advancing Globalization through High-Level Innovation and High-Quality Manufacturing

Since the beginning of the year, the Group has entered into multiple out-licensing agreements, with aggregate upfront and near-term milestone payments of US\$355 million and an aggregate potential deal value of US\$3.4 billion. These achievements demonstrate the growing international recognition of the Group's innovation capabilities and the accelerating pace of its international expansion.

The collaboration with STADA represents an important expansion of the Group's globalization strategy, extending its international partnerships into biologics manufacturing and global supply. Building on the Group's track record in out-licensing and regional collaborations for innovative drugs, this collaboration further strengthens and broadens the Group's international partnership network.

The collaboration also reflects strong international recognition of the Group's ability to develop and manufacture complex biologics. The Group continues to invest in manufacturing infrastructure and currently has a biologics manufacturing capacity of 126,000 liters^[1]. With robust quality systems and deep technical expertise, the Group can meet stringent global regulatory requirements and ensure reliable commercial-scale supply. This collaboration further demonstrates that the Group's biologics platform meets the standards of established international partners and can effectively support product commercialization in regulated markets worldwide.

Leveraging its leading innovation capabilities and large-scale manufacturing advantages, the Group is steadily advancing its globalization strategy. It will continue to integrate high-quality global industry resources and collaborate with global partners to make more innovative medicines available to patients around the world.

Expanding Global Access through Biosimilars

Pembrolizumab is a humanized anti-PD-1 monoclonal antibody approved for the treatment of dozens of cancers, including lung cancer, gastric cancer, liver cancer and endometrial cancer, and is one of the most widely used oncology medicines globally. The reference product, KEYTRUDA® and KEYTRUDA QLEX®, generated approximately US\$31.7 billion in global sales in 2025, making it the world's best-selling oncology medicine. As relevant intellectual-property protections expire, high-quality biosimilars are expected to reduce drug costs, expand patient access and support the sustainability of healthcare systems globally. As relevant intellectual property protections expire, high-quality biosimilars are expected to lower drug costs, broaden patient access, and support healthcare system sustainability worldwide.

Between 2025 and 2034, the global biologics sector is expected to see a wave of patent expirations. In the United States alone, 118 biologic medicines will lose patent protection, with combined sales exceeding US\$230 billion, underscoring a significant opportunity for biosimilars^[2].

The Group is capitalizing on these opportunities and steadily expanding its biosimilar pipeline. To date, it has 8 biosimilars approved in China, with several more in development. This collaboration with STADA marks a significant step forward in the Group's overseas biologics business and lays a solid

foundation for the global expansion of its biosimilar portfolio. Leveraging efficient R&D capabilities, stable manufacturing quality and significant cost advantages, the Group has built a globally competitive biologics platform.

About STADA

STADA is headquartered in Bad Vilbel, Germany. STADA focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA sells its products in over 100 countries. In financial year 2025, STADA achieved group sales of €4,296 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 961 million. As of 31 December 2025, STADA employed 11,670 people worldwide.

Notes:

[1] Of which 40,000L is under construction

[2] IQVIA

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 28 September 2026

As at the date of this announcement, the Board of the Company comprises five executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive Directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.